ibandronic acid has been researched along with Hip Fractures in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, S; Hu, Y; Ke, Z; Lv, M; Shen, J; Song, L; Wu, K; Xu, K; Yuan, Y | 1 |
| Bonel, H; Everts-Graber, J; Gahl, B; Häuselmann, H; Lehmann, D; Lehmann, T; Reichenbach, S; Studer, U; Ziswiler, HR | 1 |
| Ciornohac, JF; Mathonet, PY; Willems, S | 1 |
| Reid, IR | 1 |
| Barr, CE; Blumentals, WA; Harley, C; Harris, ST; Poston, SA; Reginster, JY; Silverman, SL | 1 |
| Abelson, A; Gold, DT; Lange, JL; Ringe, JD; Thomas, T | 1 |
| Nonaka, K; Uchiyama, S | 1 |
| Chesnut, CH; Gass, ML; Hamdy, RC; Holick, MF; Leib, ES; Lewiecki, ME; Maricic, M; Watts, NB | 1 |
3 review(s) available for ibandronic acid and Hip Fractures
| Article | Year |
|---|---|
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
Topics: Bone Density; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures | 2022 |
[Assessment of volumetric bone mineral density and geometry for hip with clinical CT device].
Topics: Aged; Aged, 80 and over; Bone Density; Densitometry; Diphosphonates; Female; Femur; Hip Fractures; Humans; Ibandronic Acid; Life Style; Middle Aged; Risk; Teriparatide; Tomography, X-Ray Computed | 2011 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Diet; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fish Oils; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide; Vitamin D; Vitamin D Deficiency | 2005 |
5 other study(ies) available for ibandronic acid and Hip Fractures
| Article | Year |
|---|---|
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Registries; Spinal Fractures; Zoledronic Acid | 2023 |
[Subtrochanteric pathological fracture on bisphosphonates].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Spontaneous; Hip Fractures; Humans; Ibandronic Acid | 2018 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Hip Fractures; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies | 2009 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Etidronic Acid; Female; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; United States | 2010 |